Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 06:01 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Study Evaluating Safety and Tolerability of Vabicaserin in Patients With Sudden Worsening of Schizophrenia
NCT00768612 · Wyeth is now a wholly owned subsidiary of Pfizer · PHASE2 · withdrawn · last registry update 2013-01-29 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, Wyeth is now a wholly owned subsidiary of Pfizer |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against HTR2C within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2014-01-15Results posted on the registry: Washington University School of Medicine, Olanzapine + Ziprasidone (NCT00910988)
- 2013-12-05Results posted on the registry: Icahn School of Medicine at Mount Sinai, Risperidone + Olanzapine (NCT00044655)
- 2013-07-19Results posted on the registry: Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Ziprasidone oral capsules + placebo oral capsules (NCT00257166)
- 2013-06-19Results posted on the registry: Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Ziprasidone HCL (oral) (NCT00748566)
- 2013-06-17Results posted on the registry: University of Maryland, Baltimore, a drug against HTR2C (NCT00176436)
- 2013-05-21Phase 3 first posted: University of Cincinnati, Omega + Placebo (NCT01858948)
- 2013-05-06Results posted on the registry: Bronx Psychiatric Center, ziprasidone (NCT00458211)
- 2013-04-04Results posted on the registry: University of Cincinnati, Topiramate + Placebo (NCT00394095)
- 2012-11-29Phase 3 first posted: Astellas Pharma Inc, FK949E (NCT01737268)
- 2012-11-12Phase 3 first posted: Astellas Pharma Inc, FK949E + Placebo (NCT01725308)
- 2012-07-09Results posted on the registry: Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Ziprasidone HCL (oral) (NCT01113541)
- 2012-06-12Phase 3 first posted: Organon and Co, Asenapine + Placebo Asenapine (NCT01617187)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision